• Molecular Partners posted a July 15, 2026 update on its bispecific Radio-DARPin radioligand therapy strategy, presented at the Gordon Research Conference.
• Highlight centered on multispecific Radio-DARPins designed to address tumor heterogeneity by engaging multiple targets to improve precision.
• Lead DLL3 program MP0712 remains in a US Phase 1/2a trial; mesothelin-targeting MP0726 is working toward first human imaging this year.
• Presentation copy to be posted on the company website under Scientific Documents.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Molecular Partners AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607150100PRIMZONEFULLFEED9762212) on July 15, 2026, and is solely responsible for the information contained therein.